特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
945465

糖尿病治療薬の世界市場 (2020~2026年)

Antidiabetics Market Size By Product, By Patient Population, By Route of Administration, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 202 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.14円
糖尿病治療薬の世界市場 (2020~2026年)
出版日: 2020年06月12日
発行: Global Market Insights Inc.
ページ情報: 英文 202 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病治療薬の市場は、糖尿病の有病率の上昇、医薬品開発の増加、経口糖尿病治療薬の高い導入率などの要因から、今後数年で指数関数的に成長すると予測されています。製品区分別で見ると、DPP-IV部門が2019年に80億米ドルを超える収益を示しました。DPP-IVは、体重増加を引き起こすことなく空腹時と食後の血糖値を低下させるもので、2型糖尿病患者に広く使用されています。投薬経路別では、インスリン注射器/インスリンペンの部門が15.5%を超える収益シェアを占めており、予測期間中は大幅な成長が見込まれます。インスリンペンの使いやすさやインスリン注射の柔軟性から、糖尿病の管理が改善され、糖尿病患者の生活の質が維持されます。

当レポートでは、世界の糖尿病治療薬の市場を調査し、市場および製品の概要、市場成長への各種影響因子の分析、産業エコシステム、法規制環境、市場規模の推移・予測、製品区分・患者区分・投与経路・地域/主要国など各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

第1章 第1章 調査手法

第2章 エグゼクティブサマリー

第3章 産業考察

  • 産業区分
  • 産業の推移・予測
  • 産業への影響因子
  • 法規制環境:地域別
  • 臨床ワークフローの分析
  • 償還シナリオ:地域別
  • 成長の潜在性
  • COVID-19の影響分析
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 市場分析・予測:製品別

  • 主要動向
  • インスリン
    • 超速効型アナログ
    • 持効型アナログ
    • プレミックスインスリン
    • 短時間作用型アナログ
    • 中等度作用型アナログ
  • 薬剤クラス
    • アルファグルコシダーゼ阻害剤
    • ビグアナイド
    • スルホニル尿素
    • GLP-1アゴニスト
    • DPP-IV阻害剤
    • メグリチニド
    • SGLT-II阻害剤
    • チアゾリジンジオン

第5章 市場分析・予測:患者区分別

  • 主要動向
  • 小児
  • 成人
  • 高齢者

第6章 市場分析・予測:投与経路別

  • 主要動向
  • インスリン注射器/インスリンペン
  • インスリンポンプ
  • 静脈内注入
  • 経口
  • その他

第7章 市場分析・予測:地域別

  • 地域動向
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア

第8章 企業プロファイル

  • Competitive dashboard, 2019
  • AstraZeneca
  • Bayer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Halozyme Therapeutics
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk
  • Oramed Pharmaceuticals Inc.
  • Pfizer
  • Sanofi
  • Takeda Pharmaceutical
図表

Data Tables

  • TABLE 1. Antidiabetics industry 360 degree synopsis, 2015 - 2019
  • TABLE 2. Global antidiabetics market, 2015 - 2019 (USD Million)
  • TABLE 3. Global antidiabetics market, 2020 - 2026 (USD Million)
  • TABLE 4. Global antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 5. Global antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 6. Global antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 7. Global antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 8. Global antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 9. Global antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 10. Global antidiabetics market, by region, 2015 - 2019 (USD Million)
  • TABLE 11. Global antidiabetics market, by region, 2020 - 2026 (USD Million)
  • TABLE 12. Industry impact forces
  • TABLE 13. Rapid acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 14. Rapid acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 15. Long acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 16. Long acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 17. Premixed insulin market size, by region, 2015 - 2019 (USD Million)
  • TABLE 18. Premixed insulin market size, by region, 2020 - 2026 (USD Million)
  • TABLE 19. Short acting analog market size, by region, 2015 - 2019 (USD Million)
  • TABLE 20. Short acting analog market size, by region, 2020 - 2026 (USD Million)
  • TABLE 21. Intermediate acting insulin market size, by region, 2015 - 2019 (USD Million)
  • TABLE 22. Intermediate acting insulin market size, by region, 2020 - 2026 (USD Million)
  • TABLE 23. Drug class market size, by region, 2015 - 2019 (USD Million)
  • TABLE 24. Drug class market size, by region, 2020 - 2026 (USD Million)
  • TABLE 25. Alpha glucosidase inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 26. Alpha glucosidase inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 27. Biguanides market size, by region, 2015 - 2019 (USD Million)
  • TABLE 28. Biguanides market size, by region, 2020 - 2026 (USD Million)
  • TABLE 29. Sulphonylureas market size, by region, 2015 - 2019 (USD Million)
  • TABLE 30. Sulphonylureas market size, by region, 2020 - 2026 (USD Million)
  • TABLE 31. GLP-1 (Glucagon like peptide) agonists market size, by region, 2015 - 2019 (USD Million)
  • TABLE 32. GLP-1 (Glucagon like peptide) agonists market size, by region, 2020 - 2026 (USD Million)
  • TABLE 33. DPP-IV (Dipeptidyl Peptidase) inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 34. DPP-IV (Dipeptidyl Peptidase) inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 35. Meglitinides market size, by region, 2015 - 2019 (USD Million)
  • TABLE 36. Meglitinides market size, by region, 2020 - 2026 (USD Million)
  • TABLE 37. SGLT-II (Sodium Glucose Transport Proteins) inhibitors market size, by region, 2015 - 2019 (USD Million)
  • TABLE 38. SGLT-II (Sodium Glucose Transport Proteins) inhibitors market size, by region, 2020 - 2026 (USD Million)
  • TABLE 39. Thiazolidinedione market size, by region, 2015 - 2019 (USD Million)
  • TABLE 40. Thiazolidinedione market size, by region, 2020 - 2026 (USD Million)
  • TABLE 41. Pediatric market size, by region, 2015 - 2019 (USD Million)
  • TABLE 42. Pediatric market size, by region, 2020 - 2026 (USD Million)
  • TABLE 43. Adult market size, by region, 2015 - 2019 (USD Million)
  • TABLE 44. Adult market size, by region, 2020 - 2026 (USD Million)
  • TABLE 45. Geriatric market size, by region, 2015 - 2019 (USD Million)
  • TABLE 46. Geriatric market size, by region, 2020 - 2026 (USD Million)
  • TABLE 47. Insulin syringe/ Insulin pen market size, by region, 2015 - 2019 (USD Million)
  • TABLE 48. Insulin syringe/ Insulin pen market size, by region, 2020 - 2026 (USD Million)
  • TABLE 49. Insulin pump market size, by region, 2015 - 2019 (USD Million)
  • TABLE 50. Insulin pump market size, by region, 2020 - 2026 (USD Million)
  • TABLE 51. Intravenous infusion market size, by region, 2015 - 2019 (USD Million)
  • TABLE 52. Intravenous infusion market size, by region, 2020 - 2026 (USD Million)
  • TABLE 53. Oral market size, by region, 2015 - 2019 (USD Million)
  • TABLE 54. Oral market size, by region, 2020 - 2026 (USD Million)
  • TABLE 55. Others market size, by region, 2015 - 2019 (USD Million)
  • TABLE 56. Others market size, by region, 2020 - 2026 (USD Million)
  • TABLE 57. North America market, by country, 2015 - 2019 (USD Million)
  • TABLE 58. North America market, by country, 2020 - 2026 (USD Million)
  • TABLE 59. North America antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 60. North America antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 61. North America antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 62. North America antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 63. North America antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 64. North America antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 65. North America antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 66. North America antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 67. North America antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 68. North America antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 69. U.S. antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 70. U.S. antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 71. U.S. antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 72. U.S. antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 73. U.S. antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 74. U.S. antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 75. U.S. antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 76. U.S. antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 77. U.S. antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 78. U.S. antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 79. Canada antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 80. Canada antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 81. Canada antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 82. Canada antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 83. Canada antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 84. Canada antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 85. Canada antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 86. Canada antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 87. Canada antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 88. Canada antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 89. Europe market, by country, 2015 - 2019 (USD Million)
  • TABLE 90. Europe market, by country, 2020 - 2026 (USD Million)
  • TABLE 91. Europe antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 92. Europe antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 93. Europe antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 94. Europe antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 95. Europe antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 96. Europe antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 97. Europe antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 98. Europe antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 99. Europe antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 100. Europe antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 101. Germany antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 102. Germany antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 103. Germany antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 104. Germany antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 105. Germany antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 106. Germany antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 107. Germany antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 108. Germany antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 109. Germany antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 110. Germany antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 111. UK antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 112. UK antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 113. UK antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 114. UK antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 115. UK antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 116. UK antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 117. UK antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 118. UK antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 119. UK antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 120. UK antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 121. France antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 122. France antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 123. France antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 124. France antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 125. France antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 126. France antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 127. France antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 128. France antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 129. France antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 130. France antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 131. Italy antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 132. Italy antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 133. Italy antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 134. Italy antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 135. Italy antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 136. Italy antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 137. Italy antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 138. Italy antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 139. Italy antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 140. Italy antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 141. Spain antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 142. Spain antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 143. Spain antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 144. Spain antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 145. Spain antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 146. Spain antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 147. Spain antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 148. Spain antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 149. Spain antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 150. Spain antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 151. Asia Pacific market size, by country, 2015 - 2019 (USD Million)
  • TABLE 152. Asia Pacific market size, by country, 2020 - 2026 (USD Million)
  • TABLE 153. Asia Pacific antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 154. Asia Pacific antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 155. Asia Pacific antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 156. Asia Pacific antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 157. Asia Pacific antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 158. Asia Pacific antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 159. Asia Pacific antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 160. Asia Pacific antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 161. Asia Pacific antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 162. Asia Pacific antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 163. Japan antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 164. Japan antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 165. Japan antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 166. Japan antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 167. Japan antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 168. Japan antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 169. Japan antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 170. Japan antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 171. Japan antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 172. Japan antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 173. China antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 174. China antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 175. China antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 176. China antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 177. China antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 178. China antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 179. China antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 180. China antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 181. China antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 182. China antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 183. India antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 184. India antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 185. India antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 186. India antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 187. India antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 188. India antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 189. India antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 190. India antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 191. India antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 192. India antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 193. Australia antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 194. Australia antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 195. Australia antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 196. Australia antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 197. Australia antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 198. Australia antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 199. Australia antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 200. Australia antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 201. Australia antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 202. Australia antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 203. Latin America market size, by country, 2015 - 2019 (USD Million)
  • TABLE 204. Latin America market size, by country, 2020 - 2026 (USD Million)
  • TABLE 205. Latin America antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 206. Latin America antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 207. Latin America antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 208. Latin America antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 209. Latin America antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 210. Latin America antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 211. Latin America antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 212. Latin America antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 213. Latin America antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 214. Latin America antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 215. Brazil antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 216. Brazil antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 217. Brazil antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 218. Brazil antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 219. Brazil antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 220. Brazil antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 221. Brazil antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 222. Brazil antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 223. Brazil antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 224. Brazil antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 225. Mexico antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 226. Mexico antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 227. Mexico antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 228. Mexico antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 229. Mexico antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 230. Mexico antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 231. Mexico antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 232. Mexico antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 233. Mexico antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 234. Mexico antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 235. MEA market size, by country, 2015 - 2019 (USD Million)
  • TABLE 236. MEA market size, by country, 2020 - 2026 (USD Million)
  • TABLE 237. MEA antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 238. MEA antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 239. MEA antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 240. MEA antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 241. MEA antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 242. MEA antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 243. MEA antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 244. MEA antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 245. MEA antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 246. MEA antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 247. South Africa antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 248. South Africa antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 249. South Africa antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 250. South Africa antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 251. South Africa antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 252. South Africa antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 253. South Africa antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 254. South Africa antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 255. South Africa antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 256. South Africa antidiabetics market, by route of administration, 2020 - 2026 (USD Million)
  • TABLE 257. Saudi Arabia antidiabetics market, by product, 2015 - 2019 (USD Million)
  • TABLE 258. Saudi Arabia antidiabetics market, by product, 2020 - 2026 (USD Million)
  • TABLE 259. Saudi Arabia antidiabetics market, by insulin, 2015 - 2019 (USD Million)
  • TABLE 260. Saudi Arabia antidiabetics market, by insulin, 2020 - 2026 (USD Million)
  • TABLE 261. Saudi Arabia antidiabetics market, by drug class, 2015 - 2019 (USD Million)
  • TABLE 262. Saudi Arabia antidiabetics market, by drug class, 2020 - 2026 (USD Million)
  • TABLE 263. Saudi Arabia antidiabetics market, by patient population, 2015 - 2019 (USD Million)
  • TABLE 264. Saudi Arabia antidiabetics market, by patient population, 2020 - 2026 (USD Million)
  • TABLE 265. Saudi Arabia antidiabetics market, by route of administration, 2015 - 2019 (USD Million)
  • TABLE 266. Saudi Arabia antidiabetics market, by route of administration, 2020 - 2026 (USD Million)

Charts & Figures

  • FIG.1. U.S. states with highest incidence of type 2 diabetes in the year 2016
  • FIG.2. Antidiabetics market, 2015 - 2026 (USD Million)
  • FIG.3. Clinical workflow analysis for cost optimization in middle- and low-income countries
  • FIG.4. Growth potential analysis, by product
  • FIG.5. Growth potential analysis, by patient population
  • FIG.6. Growth potential analysis, by route of administration
  • FIG.7. Porter's analysis
  • FIG.8. PESTEL analysis
  • FIG.9. Company share analysis, 2019
  • FIG.10. Competitive dashboard, 2019
目次
Product Code: 504

Title:
Antidiabetics Market Size By Product (Insulin {Rapid Acting, Long Acting, Premixed Insulin, Short Acting, Intermediate Acting}, Drug Class {Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolidinedione}), By Patient Population (Pediatric, Adult, Geriatric), By Route of Administration (Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion, Oral), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026 .

The antidiabetic market is projected to expand exponentially over the coming years owing to the rising prevalence of diabetes, increasing drug development, and high retail adoption of oral antidiabetics. Antidiabetic drugs are basically medicines which are specifically developed to stabilize and control blood glucose levels among people who are diagnosed with diabetes.

Antidiabetic drugs are generally used to manage the conditions associated diabetes. These drugs essentially help patients with their diabetes by keeping their condition under control. this effectively lowers their risk of developing any diabetes-related complications.

Diabetes patients might have to consume antidiabetic drugs for their entire lives so as to control their blood glucose levels and also to prevent hyperglycemia and hypoglycemia. This creates an immense demand for these drugs in the pharmaceutical industry, ensuring market growth.

The anti-diabetic market is segmented in terms of product, patient population, route of administration, and regional landscape.

Based on product, the antidiabetic market is classified into insulin, and drug class. The drug class segment is further classified into thiazolidinedione, SGLT-II, meglitinides, DPP-IV, GLP-I, sulphonylureas, biguanides, and alpha glucosidase inhibitors. Among these, DPP-IV segment represented over $8.0 billion revenue in 2019. DPP-IV reduces both fasting and postprandial (after food) blood glucose levels, without causing any weight gain, and is widely used for type-2 diabetic patients.

DPP-IV usually come in pill form and are consumed orally. These are either used alone or can be used in combination with other medicines related to diabetes.

With respect to patient population, the antidiabetic market is categorized into geriatric, adult, and pediatric. Pediatric segment is likely to witness growth owing to the increasing incidence of diabetes among children owing to a high consumption of carbohydrate-rich diet. This segment is projected to witness a CAGR of over 11.5% through the analysis period.

In terms of route of administration, the overall antidiabetic market is bifurcated into oral, intravenous infusion, insulin pump, insulin syringe/ insulin pen, and others. The insulin syringe/insulin pen segment represents a revenue share of more than 15.5% and is likely to witness appreciative growth over the projected time period. Ease of use of insulin pens and the flexibility of incorporating insulin injections improves diabetes control and maintains quality of life for the diabetic patients.

Additionally, a person should replace the disposable needle after using the injection of insulin, which fuels product adoption in a considerable manner. Additionally, with proper care taken, the insulin pens tend to last for many years.

From a regional frame of reference, Europe antidiabetic market is projected to witness a CAGR of over 10.7% through the analysis period. High retail adoption of oral antidiabetics, increasing drug development and consumption of novel drugs will thus lead to growth of this region.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definitions
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Antidiabetics industry 360 degree synopsis, 2015 - 2026
    • 2.1.1. Business trends
    • 2.1.2. Product trends
    • 2.1.3. Patient population trends
    • 2.1.4. Route of administration trends
    • 2.1.5. Regional trends

Chapter 3. Antidiabetics Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2015 - 2026
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Strong product pipeline of antidiabetics
      • 3.3.1.2. Globally rising prevalence of diabetes
      • 3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity
      • 3.3.1.4. Growing adoption of oral antidiabetic drugs
      • 3.3.1.5. Rising spending on R&D for innovative drugs
    • 3.3.2. Industry pitfalls and challenges
      • 3.3.2.1. Prohibitive cost of insulin
      • 3.3.2.2. Safety issues pertaining to some diabetic drugs
  • 3.4. Regulatory landscape
    • 3.4.1. U.S.
    • 3.4.2. Europe
  • 3.5. Clinical workflow analysis
  • 3.6. Reimbursement scenario
    • 3.6.1. U.S.
    • 3.6.2. Europe
    • 3.6.3. Australia
  • 3.7. Growth potential analysis
    • 3.7.1. By product
    • 3.7.2. By patient population
    • 3.7.3. By route of administration
  • 3.8. COVID-19 impact analysis
  • 3.9. Porter's analysis
  • 3.10. Competitive landscape, 2019
  • 3.11. PESTEL analysis

Chapter 4. Antidiabetics Market, By Product

  • 4.1. Key segment trends
  • 4.2. Insulin
    • 4.2.1. Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.2. Rapid acting analog
      • 4.2.2.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.3. Long acting analog
      • 4.2.3.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.4. Premixed insulin
      • 4.2.4.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.5. Short acting analog
      • 4.2.5.1. Market size, by region, 2015-2026 (USD Million)
    • 4.2.6. Intermediate acting analog
      • 4.2.6.1. Market size, by region, 2015-2026 (USD Million)
  • 4.3. Drug class
    • 4.3.1. Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.2. Alpha glucosidase inhibitors
      • 4.3.2.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.3. Biguanides
      • 4.3.3.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.4. Sulphonylureas
      • 4.3.4.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.5. GLP-1 (Glucagon like peptide) agonists
      • 4.3.5.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.6. DPP-IV (Dipeptidyl Peptidase) inhibitors
      • 4.3.6.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.7. Meglitinides
      • 4.3.7.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.8. SGLT-II (Sodium Glucose Transport Proteins) inhibitors
      • 4.3.8.1. Market size, by region, 2015-2026 (USD Million)
    • 4.3.9. Thiazolidinedione
      • 4.3.9.1. Market size, by region, 2015-2026 (USD Million)

Chapter 5. Antidiabetics Market, By Patient Population

  • 5.1. Key segment trends
  • 5.2. Pediatric
    • 5.2.1. Market size, by region, 2015 - 2026 (USD Million)
  • 5.3. Adult
    • 5.3.1. Market size, by region, 2015 - 2026 (USD Million)
  • 5.4. Geriatric
    • 5.4.1. Market size, by region, 2015 - 2026 (USD Million)

Chapter 6. Antidiabetics Market, By Route of Administration

  • 6.1. Key segment trends
  • 6.2. Insulin syringe/ Insulin pen
    • 6.2.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.3. Insulin pump
    • 6.3.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.4. Intravenous infusion
    • 6.4.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market size, by region, 2015 - 2026 (USD Million)
  • 6.6. Others
    • 6.6.1. Market size, by region, 2015 - 2026 (USD Million)

Chapter 7. Antidiabetics Market, By Region

  • 7.1. Key regional trends
  • 7.2. North America
    • 7.2.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.2.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.2.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.2.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.2.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.2.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.2.5. U.S.
      • 7.2.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.2.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.2.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.2.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.2.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.2.6. Canada
      • 7.2.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.2.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.2.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.2.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.2.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.3. Europe
    • 7.3.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.3.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.3.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.3.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.3.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.3.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.5. Germany
      • 7.3.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.6. UK
      • 7.3.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.7. France
      • 7.3.7.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.7.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.7.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.7.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.8. Italy
      • 7.3.8.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.8.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.8.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.8.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.3.9. Spain
      • 7.3.9.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.3.9.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.3.9.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.3.9.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.3.9.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.4.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.4.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.4.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.4.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.4.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.6. China
      • 7.4.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.7. India
      • 7.4.7.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.7.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.7.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.7.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.7.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.4.8. Australia
      • 7.4.8.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.4.8.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.4.8.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.4.8.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.4.8.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.5.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.5.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.5.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.5.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.5.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.5.5. Brazil
      • 7.5.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.5.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.5.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.5.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.5.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.5.6. Mexico
      • 7.5.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.5.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.5.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.5.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.5.6.3. Market size by route of administration, 2015 - 2026 (USD Million)
  • 7.6. Middle East & Africa (MEA)
    • 7.6.1. Market size by country, 2015 - 2026 (USD Million)
    • 7.6.2. Market size by product, 2015 - 2026 (USD Million)
      • 7.6.2.1. Market size, by insulin, 2015 - 2026 (USD Million)
      • 7.6.2.2. Market size, by drug class, 2015 - 2026 (USD Million)
    • 7.6.3. Market size by patient population, 2015 - 2026 (USD Million)
    • 7.6.4. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.6.5.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.6.5.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.6.5.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.6.5.3. Market size by route of administration, 2015 - 2026 (USD Million)
    • 7.6.6. Saudi Arabia
      • 7.6.6.1. Market size by product, 2015 - 2026 (USD Million)
        • 7.6.6.1.1. Market size, by insulin, 2015 - 2026 (USD Million)
        • 7.6.6.1.2. Market size, by drug class, 2015 - 2026 (USD Million)
      • 7.6.6.2. Market size by patient population, 2015 - 2026 (USD Million)
      • 7.6.6.3. Market size by route of administration, 2015 - 2026 (USD Million)

Chapter 8. Company Profiles

  • 8.1. Competitive dashboard, 2019
  • 8.2. AstraZeneca
    • 8.2.1. Business overview
    • 8.2.2. Financial data
    • 8.2.3. Product landscape
    • 8.2.4. Strategic outlook
    • 8.2.5. SWOT analysis
  • 8.3. Bayer Corporation
    • 8.3.1. Business overview
    • 8.3.2. Financial data
    • 8.3.3. Product landscape
    • 8.3.4. Strategic outlook
    • 8.3.5. SWOT analysis
  • 8.4. Boehringer Ingelheim
    • 8.4.1. Business overview
    • 8.4.2. Financial data
    • 8.4.3. Product landscape
    • 8.4.4. Strategic outlook
    • 8.4.5. SWOT analysis
  • 8.5. Bristol-Myers Squibb
    • 8.5.1. Business overview
    • 8.5.2. Financial data
    • 8.5.3. Product landscape
    • 8.5.4. Strategic outlook
    • 8.5.5. SWOT analysis
  • 8.6. Eli Lilly
    • 8.6.1. Business overview
    • 8.6.2. Financial data
    • 8.6.3. Product landscape
    • 8.6.4. Strategic outlook
    • 8.6.5. SWOT analysis
  • 8.7. Halozyme Therapeutics
    • 8.7.1. Business overview
    • 8.7.2. Financial data
    • 8.7.3. Product landscape
    • 8.7.4. Strategic outlook
    • 8.7.5. SWOT analysis
  • 8.8. Johnson & Johnson
    • 8.8.1. Business overview
    • 8.8.2. Financial data
    • 8.8.3. Product landscape
    • 8.8.4. Strategic outlook
    • 8.8.5. SWOT analysis
  • 8.9. Merck & Co. Inc.
    • 8.9.1. Business overview
    • 8.9.2. Financial data
    • 8.9.3. Product landscape
    • 8.9.4. Strategic outlook
    • 8.9.5. SWOT analysis
  • 8.10. Novartis AG
    • 8.10.1. Business overview
    • 8.10.2. Financial data
    • 8.10.3. Product landscape
    • 8.10.4. Strategic outlook
    • 8.10.5. SWOT analysis
  • 8.11. Novo Nordisk
    • 8.11.1. Business overview
    • 8.11.2. Financial data
    • 8.11.3. Product landscape
    • 8.11.4. Strategic outlook
    • 8.11.5. SWOT analysis
  • 8.12. Oramed Pharmaceuticals Inc.
    • 8.12.1. Business overview
    • 8.12.2. Financial data
    • 8.12.3. Product landscape
    • 8.12.4. Strategic outlook
    • 8.12.5. SWOT analysis
  • 8.13. Pfizer
    • 8.13.1. Business overview
    • 8.13.2. Financial data
    • 8.13.3. Product landscape
    • 8.13.4. Strategic outlook
    • 8.13.5. SWOT analysis
  • 8.14. Sanofi
    • 8.14.1. Business overview
    • 8.14.2. Financial data
    • 8.14.3. Product landscape
    • 8.14.4. Strategic outlook
    • 8.14.5. SWOT analysis
  • 8.15. Takeda Pharmaceutical
    • 8.15.1. Business overview
    • 8.15.2. Financial data
    • 8.15.3. Product landscape
    • 8.15.4. Strategic outlook
    • 8.15.5. SWOT analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.